ACUTAAS
vs
B
BSE Sensex 30
ACUTAAS
Over the past 12 months, ACUTAAS has significantly outperformed BSE Sensex 30, delivering a return of +56% compared to the BSE Sensex 30's +10% growth.
Stocks Performance
ACUTAAS vs BSE Sensex 30
Performance Gap
ACUTAAS vs BSE Sensex 30
Performance By Year
ACUTAAS vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Acutaas Chemicals Ltd
Glance View
Acutaas Chemicals Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-09-14. The company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
